EDC for longevity clinical trials: aging and longevity endpoints, ePRO, and 21 CFR Part 11–aligned controls.
21 CFR Part 11 aligned · HIPAA-aligned security · No credit card required
Longevity studies often combine exploratory biomarkers, clinical labs, wearable-derived summaries, functional measures, and participant-reported outcomes across repeated time points. The challenge is not just collecting each result; it is keeping the timeline coherent. Baseline, interim, and long-term follow-up data need to stay linked to the same participant, visit window, intervention exposure, and protocol version. Capture lets teams configure CRFs for the biomarker strategy defined in the protocol. Forms can capture sample collection dates, lab result values, reference ranges, fasting status, collection conditions, assay notes, and whether a value was repeated or excluded. If the study collects multiple classes of biomarkers, the EDC can keep them structured by visit and endpoint rather than placing everything into general notes or offline spreadsheets. That structure matters for healthspan research because endpoints may change slowly and signals can be subtle. When a dataset combines biomarkers with adherence, safety, functional assessments, and PROs, reviewers need confidence that each value belongs to the right participant and time point. A controlled EDC gives the team a cleaner foundation for interim review, exploratory analysis, publication, and follow-up studies.
Longevity trials rarely rely on biomarkers alone. Many protocols also measure function, quality of life, sleep, activity, cognition, fatigue, mood, or other healthspan-related outcomes. Some of these measures are collected by site staff during visits, while others are reported by participants between visits. If those data streams are managed separately, the study team can lose the context needed to interpret whether a biomarker change corresponds to a meaningful participant outcome. Capture combines EDC and ePRO so clinical and participant-reported measures can be collected under one study workflow. Site forms can capture functional assessments, clinician observations, protocol deviations, concomitant interventions, and safety events. ePRO can support scheduled questionnaires or diaries for symptoms, sleep, energy, treatment burden, or perceived function. The same participant identifiers and audit model apply across both data types. For longevity teams, this helps connect the biological and practical sides of the study. A change in an aging-related marker may be more persuasive when paired with consistent functional or quality-of-life data. Conversely, participant-reported improvement can be interpreted more carefully when the clinical dataset includes adherence, safety, and objective measures from the same period.
Longevity research is often exploratory, fast-moving, and multidisciplinary. Study teams may refine endpoints, add follow-up measures, or adjust data review priorities as early findings emerge. That flexibility is useful, but it creates governance risk if changes are handled through informal spreadsheets or undocumented process changes. Capture helps keep exploratory work disciplined. Study builders can update forms and schedules while preserving audit history. Role-based access controls who can enter, review, query, sign, or export data. Query workflows give monitors and data managers a structured way to resolve missing or inconsistent records before analysis. Consent and participant records stay connected to the clinical dataset, which is important when follow-up windows are long or when additional assessments are added. This governance layer is valuable even when the study is not a traditional drug trial. Sponsors, academic groups, and longevity clinics still need credible data if they plan to publish, support claims, or make development decisions. Capture gives those teams a practical system for collecting emerging healthspan endpoints without giving up traceability.
Overview
Longevity clinical trials study interventions aimed at aging, healthspan, and related biomarkers and outcomes. Your EDC must support consent, CRFs, optional ePRO and patient-reported outcomes, biomarker and lab data, and full auditability for regulatory and publication use. Capture provides EDC, eConsent, ePRO, and safety in one platform with 21 CFR Part 11–aligned controls and HIPAA-aligned infrastructure, so longevity study teams can capture clinical and PRO data with one audit trail.
Longevity studies often combine biomarkers, functional assessments, and patient-reported outcomes. You need one system that handles consent, CRFs, and ePRO with the same audit trail and access controls. Legacy EDC may lack flexibility for emerging longevity endpoints. Capture is built for flexible study designs with controls aligned with 21 CFR Part 11 and HIPAA-aligned security.
FAQ
Explore the platform with a free sandbox. No sales call required.
Explore platform